CVS will exit Obamacare plans in 2026, affecting 1 million members across 17 states, and close stores amid pharmacy desert ...

CVS Health plans to exit the individual Obamacare health insurance business next year, leaving 1 million people in 17 states ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

CVS Health raised its full-year profit forecast on Thursday and said it plans to exit the market for Obamacare health ...

The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

CVS Health hiked its 2025 forecast above Wall Street’s expectations after improving Medicare benefits contributed to a better ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...